Donor cell engineering with GSK3 inhibitor–loaded nanoparticles enhances engraftment after in utero transplantation
Journal article published in 2019 by
Stavros P. Loukogeorgakis,
Camila G. Fachin,
Andre I. B. S. Dias 
,
Haiying Li,
Li Tang ,
Aimee G. Kim ,
Jesse D. Vrecenak,
John D. Stratigis,
Nicholas J. Ahn ,
Ilana Nissim,
Izhtak Nissim,
Antonio F. Moron,
Jose L. Martins,
William H. Peranteau,
Paolo De Coppi
and other authors.
,
Haiying Li,
Li Tang ,
Aimee G. Kim ,
Jesse D. Vrecenak,
John D. Stratigis,
Nicholas J. Ahn ,
Ilana Nissim,
Izhtak Nissim,
Antonio F. Moron,
Jose L. Martins,
William H. Peranteau,
Paolo De Coppi
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Intrauterine transplantation induces tolerance in the setting of the immature immue system but is hampered by low levels of engraftment. Glycogen synthase kinase 3 (GSK3) inhibition enhances stem cell proliferation, and Loukogeorgakis and colleagues report excellent engraftment in utero in mice following surface attachment of nanoparticles loaded with GSK3 inhibitor to donor stem cells.